Publication:

Ephedra and the FDA

Loading...
Thumbnail Image

Date

2001

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Ephedra and the FDA (2001 Third Year Paper)

Abstract

The adverse events experienced after ingesting ephedra and other dietary supplements have demonstrated the need for FDA intervention. The FDA has an important role to play in safeguarding the health and safety of the American public. The FDA has been criticized as contravening the Congressional intent underlying DSHEA because of its attempts to regulate the dietary supplement industry, when in fact, the FDA has not overstepped its bounds. The agency has only taken the measures it felt necessary to protect the public and "implement a complex and ambiguous law." However, the FDA does need to focus on more effective procedures and systems for collecting adverse event reports and could take additional steps toward public awareness. In order for the FDA to address the overall problems with the regulating the dietary supplement industry efficiently and effectively, they will need additional funding.

Description

Other Available Sources

Research Data

Keywords

Food and Drug Law, ephedra, FDA, regulation, dietary supplement

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories